avkАрхивъ внутренней медициныThe Russian Archives of Internal Medicine2226-67042411-6564“SINAPS” LLC10.20514/2226-6704-2012-0-3-16-19avk-93Research ArticleОБЩЕЕ ДЕЛОЛЕКАРСТВА И ПЕЧЕНЬ: НЕИЗМЕННЫЙ ТАНДЕМ. ЧАСТЬ 2ЛЕКАРСТВА И ПЕЧЕНЬ: НЕИЗМЕННЫЙ ТАНДЕМ. ЧАСТЬ 2ЕреминаЕ. Ю.ЕреминаЕ. Ю.

кафедра пропедевтики внутренних болезней, г. Саранск

кафедра пропедевтики внутренних болезней, г. Саранск

eeu61@mail.ruФГБОУ ВПО Мордовский государственный университет им. Н.П. ОгареваРоссияФГБОУ ВПО Мордовский государственный университет им. Н.П. ОгареваRussian Federation201228062012031619Copyright © Еремина Е.Ю., 20122012Еремина Е.Ю.Еремина Е.Ю.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medarhive.ru/jour/article/view/93

В статье приведены современные данные по проблеме лекарственных поражений печени (ЛПП) и ряд клинических наблюдений автора. Указаны факторы риска ЛПП, основные механизмы и клинические варианты поражения печени, а также принципы их диагностики и лечения.

 

 

Начало читайте в № 2

Начало читайте в № 2.

The article is devoted to the up-to-date data of the drug-induced liver diseases (DILD) problem and series of the clinical monitoring accomplished by the author. It contains the DILD risk factors, the main mechanisms and the clinical variants of the liver injuries and the main DILD diagnostics and treatment principles.

лекарственные поражения печенимеханизмыклинические вариантыпринципы диагностикилечениеdrug-induced liver diseasesmechanismsclinical variantsdiagnostics principlestreatmentReferencesМорозов С.В., Кучерявый Ю.А. Гепатопротекторы в клинической практике: рациональные аспекты использования. Пособие для врачей. М., 2011. 28 с.Морозов С.В., Кучерявый Ю.А. Гепатопротекторы в клинической практике: рациональные аспекты использования. Пособие для врачей. М., 2011. 28 с.Новиков В.Е., Климкина Е.И. Фармакология гепатопротекторов // Обзор клин. фармакол. лекарственной терапии. 2005. Т. 4, № 1. С. 2–20.Новиков В.Е., Климкина Е.И. Фармакология гепатопротекторов // Обзор клин. фармакол. лекарственной терапии. 2005. Т. 4, № 1. С. 2–20.Хазанов А.И. Острый лекарственный гепатит. Гастроэнтерология и гепатология: диагностика и лечение. Под ред. А.В. Калинина, А.И. Хазанова. М., 2007. С. 416–420.Хазанов А.И. Острый лекарственный гепатит. Гастроэнтерология и гепатология: диагностика и лечение. Под ред. А.В. Калинина, А.И. Хазанова. М., 2007. С. 416–420.Шерлок Ш., Дули Дж. Заболевания печени и желчных путей. М., 1999.Шерлок Ш., Дули Дж. Заболевания печени и желчных путей. М., 1999.Adukauskiene D., Dockiene I., Naginiene R. et al. Acute liver failure in Lithuania // Medicina (Kaunas, Lithuania). 2008. Vol. 44, № 7. Р. 536–40.Adukauskiene D., Dockiene I., Naginiene R. et al. Acute liver failure in Lithuania // Medicina (Kaunas, Lithuania). 2008. Vol. 44, № 7. Р. 536–40.Aithal G.P., Watkins P.B., Andrade R.J. et al. Case definition and phenotype standardization in drug–induced liver injury // Clinical pharmacology and therapeutics. 2011. Vol. 89, № 6. Р. 806–15.Aithal G.P., Watkins P.B., Andrade R.J. et al. Case definition and phenotype standardization in drug–induced liver injury // Clinical pharmacology and therapeutics. 2011. Vol. 89, № 6. Р. 806–15.Andrade R.J., Agundez J.A., Lucena M.I. et al. Pharmacogenomics in drug induced liver injury // Curr. Drug Metab. 2009. Vol. 10, № 9. Р. 956–70.Andrade R.J., Agundez J.A., Lucena M.I. et al. Pharmacogenomics in drug induced liver injury // Curr. Drug Metab. 2009. Vol. 10, № 9. Р. 956–70.Andrade R.J., Lucena M.I., Alonso A. et al. HLA class II genotype influences the type of liver injury in drug–induced idiosyncratic liver disease // Hepatology. 2004. Vol. 39, № 6. Р. 1603–12.Andrade R.J., Lucena M.I., Alonso A. et al. HLA class II genotype influences the type of liver injury in drug–induced idiosyncratic liver disease // Hepatology. 2004. Vol. 39, № 6. Р. 1603–12.Andrade R., Lucena M., Fernandes M.C. et al. Drug-induced liver injures analisis of 461 residences submitted to the Spanish registry a 10-years period // Gastroenterology. 2005. № 129. Р. 512–521.Andrade R., Lucena M., Fernandes M.C. et al. Drug-induced liver injures analisis of 461 residences submitted to the Spanish registry a 10-years period // Gastroenterology. 2005. № 129. Р. 512–521.Andrade R., Lucena M., Kaplowitz N., Pachkova K. Outcome of acute idiosyncratic drug induced liver injury // J. Hepatol. 2006. № 44. Р. 1581–1588.Andrade R., Lucena M., Kaplowitz N., Pachkova K. Outcome of acute idiosyncratic drug induced liver injury // J. Hepatol. 2006. № 44. Р. 1581–1588.Bjornsson E., Jerlstad P., Bergqvist A., Olsson R. Fulminant drug–induced hepatic failure leading to death or liver transplantation in Sweden // Scandinavian journal of gastroenterology. 2005. Vol. 40, № 9. Р. 1095–101.Bjornsson E., Jerlstad P., Bergqvist A., Olsson R. Fulminant drug–induced hepatic failure leading to death or liver transplantation in Sweden // Scandinavian journal of gastroenterology. 2005. Vol. 40, № 9. Р. 1095–101.Bjornsson E., Olsson R. Outcome and prognostic markers in severe drug–induced liver disease // Hepatology. 2005. Vol. 42, № 2. Р. 481–9.Bjornsson E., Olsson R. Outcome and prognostic markers in severe drug–induced liver disease // Hepatology. 2005. Vol. 42, № 2. Р. 481–9.Buratti S., Lavine J.E. Drugs and the liver: advances in metabolism, toxicity, and therapeutics // Curr. Opin. Pediatr. 2002. № 14. Р. 601–7.Buratti S., Lavine J.E. Drugs and the liver: advances in metabolism, toxicity, and therapeutics // Curr. Opin. Pediatr. 2002. № 14. Р. 601–7.Chang C.Y., Schiano T.D. Review article: drug hepatotoxicity // Alimentary pharmacology & therapeutics. 2007. Vol. 25, № 10. Р. 1135–51.Chang C.Y., Schiano T.D. Review article: drug hepatotoxicity // Alimentary pharmacology & therapeutics. 2007. Vol. 25, № 10. Р. 1135–51.Chitturi S., Farrell G.C. Drug-induced cholestasis // Semin. Gastrointest. Dis. 2001. № 122. Р. 113–24.Chitturi S., Farrell G.C. Drug-induced cholestasis // Semin. Gastrointest. Dis. 2001. № 122. Р. 113–24.Day C.P. NASH–related liver failure: one hit too many? // The American journal of gastroenterology. 2002. Vol. 97, № 8. Р. 1872–4.Day C.P. NASH–related liver failure: one hit too many? // The American journal of gastroenterology. 2002. Vol. 97, № 8. Р. 1872–4.Farrell G.C. Drugs and steatohepatitis // Semin. Liver Dis. 2002. № 22. Р. 185–94.Farrell G.C. Drugs and steatohepatitis // Semin. Liver Dis. 2002. № 22. Р. 185–94.International Consensus Meeting Criteria of drug-induced liver disorders // J. Hepatol. 1990. № 11. Р. 272–276.International Consensus Meeting Criteria of drug-induced liver disorders // J. Hepatol. 1990. № 11. Р. 272–276.Kaplowitz N. Drug induced hepatitis. In: Chronic hepatitis: metabolic, cholestatic, viral and autoimmune. Eds. M. Diel, N. Hayashi, M.P. Manns, T. Samerbruth. Dordrecht: Springer, 2007. P. 32–42.Kaplowitz N. Drug induced hepatitis. In: Chronic hepatitis: metabolic, cholestatic, viral and autoimmune. Eds. M. Diel, N. Hayashi, M.P. Manns, T. Samerbruth. Dordrecht: Springer, 2007. P. 32–42.Larrey D. Drug–induced liver disease // J. Hepatol. 2000. Vol. 32 (suppl. 1). P. 77–88.Larrey D. Drug–induced liver disease // J. Hepatol. 2000. Vol. 32 (suppl. 1). P. 77–88.Lewis J.H. Drug-induced liver disease // Med. Clin. North Am. 2000. Vol. 84. P. 1275–311.Lewis J.H. Drug-induced liver disease // Med. Clin. North Am. 2000. Vol. 84. P. 1275–311.Liu Z.X., Kaplowitz N. Immune-mediated drug-induced liver disease // Clin. Liver Dis. 2002. Vol. 6. P. 467–86.Liu Z.X., Kaplowitz N. Immune-mediated drug-induced liver disease // Clin. Liver Dis. 2002. Vol. 6. P. 467–86.Lucena M.I., Andrade R.J., Kaplowitz N. et al. Phenotypic characterization of idiosyncratic drug–induced liver injury: the influence of age and sex // Hepatology. 2009. Vol. 49, № 6. Р. 2001–9.Lucena M.I., Andrade R.J., Kaplowitz N. et al. Phenotypic characterization of idiosyncratic drug–induced liver injury: the influence of age and sex // Hepatology. 2009. Vol. 49, № 6. Р. 2001–9.Lucena M.I., Andrade R.J., Martinez C. et al. Glutathione S–transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug–induced liver injury // Hepatology. 2008. Vol. 48, № 2. Р. 588–96.Lucena M.I., Andrade R.J., Martinez C. et al. Glutathione S–transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug–induced liver injury // Hepatology. 2008. Vol. 48, № 2. Р. 588–96.Lucena M.I., Garcia–Martin E., Andrade R.J. et al. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug–induced liver injury // Hepatology. 2010. Vol. 52, № 1. Р. 303–12.Lucena M.I., Garcia–Martin E., Andrade R.J. et al. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug–induced liver injury // Hepatology. 2010. Vol. 52, № 1. Р. 303–12.Lucena M.I., Kaplowitz N., Hallal H. et al. Recurrent Drug–Induced Liver Injury (DILI) with different drugs in the Spanish Registry: The dilemma of the relationship to autoimmune hepatitis // Journal of hepatology. 2011. Feb 19.Lucena M.I., Kaplowitz N., Hallal H. et al. Recurrent Drug–Induced Liver Injury (DILI) with different drugs in the Spanish Registry: The dilemma of the relationship to autoimmune hepatitis // Journal of hepatology. 2011. Feb 19.Marschall H.U., Wagner M., Zollner G., Trauner M. Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors // Molecular pharmaceutics. 2007. Vol. 4, № 6. Р. 895–910.Marschall H.U., Wagner M., Zollner G., Trauner M. Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors // Molecular pharmaceutics. 2007. Vol. 4, № 6. Р. 895–910.Ostapowicz G., Fontana R.J., Schiodt F.V. et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States // Annals of internal medicine. 2002. Vol. 137, № 12. Р. 947–54.Ostapowicz G., Fontana R.J., Schiodt F.V. et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States // Annals of internal medicine. 2002. Vol. 137, № 12. Р. 947–54.Teschke R., Schmidt–Taenzer W., Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver–unspecific Naranjo scale precise enough to ascertain causality? // Pharmacoepidemiology and drug safety. 2011. Vol. 20, № 6. Р. 567–82.Teschke R., Schmidt–Taenzer W., Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver–unspecific Naranjo scale precise enough to ascertain causality? // Pharmacoepidemiology and drug safety. 2011. Vol. 20, № 6. Р. 567–82.Thiim M., Friedman LS. Hepatotoxicity of antibiotics and antifungals // Clin. Liver Dis. 2003. Vol. 7, № 2. Р. 381–99.Thiim M., Friedman LS. Hepatotoxicity of antibiotics and antifungals // Clin. Liver Dis. 2003. Vol. 7, № 2. Р. 381–99.Wu S.S., Chao C.S., Vargas J.H. et al. Isoniazid–related hepatic failure in children: a survey of liver transplantation centers // Transplantation. 2007. Vol. 84, № 2. Р. 173–9.Wu S.S., Chao C.S., Vargas J.H. et al. Isoniazid–related hepatic failure in children: a survey of liver transplantation centers // Transplantation. 2007. Vol. 84, № 2. Р. 173–9.Zimmerman H.J. Drug–induced liver disease // Clin. Liver Dis. 2000. Vol. 4, № 1. Р. 73–96.Zimmerman H.J. Drug–induced liver disease // Clin. Liver Dis. 2000. Vol. 4, № 1. Р. 73–96.

The authors declare that there are no conflicts of interest present.